OKYO Pharma Announces Public Offering of Ordinary Shares
14 September 2023 - 6:05AM
OKYO Pharma Announces Public Offering of Ordinary Shares
OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease (“DED”), today announced
that it intends to offer to sell its ordinary shares in an
underwritten public offering (the “Offering”). All of the ordinary
shares are to be sold by the Company. The Company expects to grant
the underwriter a 30-day option to purchase up to an additional 15%
of the number of ordinary shares sold in this Offering to cover
over-allotments, if any. The Offering is subject to market
conditions and there can be no assurance as to whether or when the
Offering may be completed, or as to the actual size or terms of the
Offering.
Freedom Capital Markets is acting as the sole
book-running manager for the Offering. Bancroft Capital is acting
as co-manager.
OKYO intends to use the net proceeds from the
Offering primarily for clinical development of the Company’s
product candidates, general corporate purposes and working
capital.
The Company has received indications of interest
from a limited number of individual and institutional investors to
purchase up to $4.0 million of our ordinary shares in a Company
best efforts registered direct offering, which if concluded would
price and close at or about the same time as this Offering. Any
shares sold by us in the registered direct offering would be at the
same price per share to the public as those sold in this Offering.
The consummation of this Offering is not conditioned on the
consummation of the registered direct offering, and neither is such
offering contingent on this Offering, and the Company cannot
provide any assurance that the proposed registered direct offering
will price or close regardless of whether this Offering prices and
closes.
The securities are being offered and sold
pursuant to a shelf registration statement on Form F-3 (File No.
333-272516), including a base prospectus, filed with the U.S.
Securities and Exchange Commission (the “SEC”) on June 8, 2023, and
declared effective on June 14, 2023. The Offering is being made
only by means of a prospectus supplement and the accompanying base
prospectus, as may be further supplemented by any free writing
prospectus and/or pricing supplement that the Company may file with
the SEC. A preliminary prospectus supplement and the accompanying
base prospectus describing the terms of the proposed Offering have
been filed with the SEC and are available on the SEC's website
at www.sec.gov. The final prospectus supplement relating to
the Offering will be filed with the SEC and will also be available
on the SEC's website. Copies of the preliminary prospectus
supplement, the final prospectus supplement and the accompanying
base prospectus relating to the Offering can also be obtained, when
available, in writing from Freedom Capital Markets, 40 Wall Street,
58th Floor, New York, NY 10005, or via email
at EquitySyndicate@freedomcapmkts.com and via telephone
at (800) 786-1469.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction.
About OKYO PharmaOKYO Pharma
Limited (Nasdaq: OKYO) is a life sciences company, focusing on the
discovery and development of novel molecules to treat inflammatory
dry eye diseases and chronic pain.
Forward-Looking
StatementsStatements in this press release may be
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that concern matters
that involve risks and uncertainties that could cause actual
results to differ materially from those anticipated or projected in
the forward-looking statements. These forward-looking statements
are not historical facts but rather are based on the Company's
current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
reflect the current beliefs and expectations of management and
include statements regarding the proposed terms of the proposed
offerings, completion, timing and size of the proposed offerings
and the expected use of proceeds from the offerings. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. Forward-looking statements are subject
to risks and uncertainties that may cause the Company’s actual
activities or results to differ materially from those indicated or
implied by any forward-looking statement, including, without
limitation, due to risks and uncertainties related to market
conditions and the satisfaction of closing conditions related to
the proposed public offering, risks disclosed in the section titled
"Risk Factors" included in the preliminary prospectus supplement
filed with the SEC on September 13, 2023, and risks disclosed
in other documents OKYO files from time to time with the SEC. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Enquiries:
OKYO Pharma
Limited |
Gary S. Jacob, Chief Executive
Officer |
+44 (0)20 7495 2379 |
|
|
|
Investor
Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024